PCSA earnings analysis
What we found in PCSA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not disclose revenue, margins, EPS, balance-sheet balances, cash flow, capex or segment results, so quarter-over-quarter and year-over-year operating trends cannot be assessed. Post-quarter developments materially increase execution and financing risk: the PCS6422 program was returned to Elion following a $650,000 settlement payment, while the company is concentrating resources on VT-7208. The Vidya Acquisition also introduces integration costs and potential dilution of up to 307,063,330 shares, or approximately 99.0% of common shares on an as-converted basis.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Vidya integration underway
- The Vidya Acquisition was completed after June 30, 2026, and management expects integration of Vidya's financial processes, systems and personnel to continue through the remainder of 2026.
- PCS6422 litigation resolved
- The PCS6422 litigation was settled on July 23, 2026; Processa paid Elion $650,000, returned the PCS6422 program, and the litigation was dismissed with prejudice on August 7, 2026.
- Pipeline refocused on VT-7208
- Processa stated that it is focusing the majority of its resources on VT-7208 across food allergy, CSU and RMS, while continuing development of PCS499, PCS12852 and PCS11T.
- Controls assessed as effective
- Management concluded that disclosure controls were effective as of June 30, 2026, and reported no material changes in internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High dependence on VT-7208
- The company said it is focusing the vast majority of its resources on VT-7208 and has no products approved for commercial sale. Failure or delay in VT-7208 development could therefore have a disproportionate impact on the business.
- Severe potential equity dilution
- Up to 307,063,330 common shares may be issued upon conversion of Series A Preferred Stock, representing approximately 99.0% of issued and outstanding common shares as of August 7, 2026 on an as-converted basis, creating substantial dilution and resale risk.
- Preferred-stock cash settlement risk
- The company must recommend approval of the Series A Preferred Stock conversion and related stockholder matters; if conversion cannot be delivered, holders may require cash settlement after 6 months from the initial issuance date, which could materially harm operations and financial condition.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text. Outlook deferred/not provided.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 7, 2026
- Processa Pharmaceuticals, in its Q1 2026 10-Q filing, reported a continuing trend of net losses, with a net loss of $3.38 million compared to $2.83 million in Q1 2025. The company remains in the clinical trial phase…
- 10-K · April 30, 2026
- Processa Pharmaceuticals continues to focus on clinical development with a reported diluted EPS of -1.3 in Q4 2026, aligning with consensus estimates, while maintaining a stable operational status due to ongoing trials.…
- 10-K · March 18, 2026
- Processa is a clinical-stage biopharmaceutical company focused on 'Next Generation Cancer' (NGC) therapies that modify metabolism/distribution of established oncology drugs. The company has enrolled and dosed the 20…
- 10-Q · May 8, 2025
- Processa Pharmaceuticals reported a net loss of $2,834,405 for the quarter ended March 31, 2025 versus a loss of $2,726,381 in the prior-year quarter, while GAAP loss per share improved to $(0.30) from $(1.11) due to a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PCSA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever